| scholarly article | Q13442814 |
| P50 | author | Erik De Clercq | Q13578863 |
| Sigrid Hatse | Q114337661 | ||
| Willy Peumans | Q116791666 | ||
| Anne-Mieke Vandamme | Q28743834 | ||
| Kristel Van Laethem | Q28743837 | ||
| Jan Balzarini | Q31332118 | ||
| Els Van Damme | Q21259178 | ||
| Dominique Schols | Q47698773 | ||
| Kurt Vermeire | Q52349537 | ||
| P2093 | author name string | Anders Bölmstedt | |
| P2860 | cites work | Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41 | Q73097938 |
| Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques | Q73814670 | ||
| Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 | Q28379182 | ||
| A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding | Q28646883 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 | Q29616093 | ||
| HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry | Q29620710 | ||
| The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry | Q24315492 | ||
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| High mannose glycans and sialic acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1 | Q28218078 | ||
| Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro | Q28321244 | ||
| A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity | Q28343321 | ||
| SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo | Q28362194 | ||
| The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication | Q28378759 | ||
| Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters | Q31431626 | ||
| Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance | Q33538414 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development | Q35137168 | ||
| Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells | Q36377366 | ||
| The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine | Q36736256 | ||
| Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection | Q37568901 | ||
| Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner | Q38301855 | ||
| Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. | Q38359755 | ||
| Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin | Q39482203 | ||
| A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure | Q39588870 | ||
| Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. | Q40788362 | ||
| Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape | Q41558189 | ||
| Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. | Q41739789 | ||
| Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. | Q41986204 | ||
| Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells | Q42163960 | ||
| Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. | Q42278214 | ||
| Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. | Q42548671 | ||
| Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine | Q42556643 | ||
| Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies | Q44190546 | ||
| The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replic | Q45876895 | ||
| A general model for the surface glycoproteins of HIV and other retroviruses. | Q49281404 | ||
| N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization | Q56935643 | ||
| Correlation between carbohydrate structures on the envelope glycoprotein gp120 of.HIV-1 and HIV-2 and syncytium inhibition with lectins | Q61054864 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 10617-10627 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins | |
| P478 | volume | 78 |
| Q34309568 | A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro |
| Q56786373 | A guided tour through the antiviral drug field |
| Q94502142 | A new chitin-binding lectin from rhizome of Setcreasea purpurea with antifungal, antiviral and apoptosis-inducing activities |
| Q38343814 | Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope |
| Q36242593 | Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. |
| Q38315888 | Anti-HIV I/II activity and molecular cloning of a novel mannose/sialic acid-binding lectin from rhizome of Polygonatum cyrtonema Hua. |
| Q33223969 | Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor |
| Q38868608 | Antiviral Activity of Synthetic Aminopyrrolic Carbohydrate Binding Agents: Targeting the Glycans of Viral gp120 to Inhibit HIV Entry. |
| Q38300956 | Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture |
| Q39876850 | Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection |
| Q38891044 | Antiviral lectins: Selective inhibitors of viral entry |
| Q38159719 | Bitter-sweet symphony: glycan-lectin interactions in virus biology |
| Q56763445 | Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120 |
| Q36758492 | Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? |
| Q57252416 | Carbohydrates on HIV: mediators of immune evasion and targets for antiviral intervention |
| Q39829308 | Clematis montana lectin, a novel mannose-binding lectin from traditional Chinese medicine with antiviral and apoptosis-inducing activities |
| Q39593941 | Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea mays strongly determine their eventual anti-HIV activity |
| Q34042632 | Ebola virus (EBOV) infection: Therapeutic strategies |
| Q36150601 | Emerging anti-HIV drugs |
| Q34004118 | Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions |
| Q34120130 | Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages |
| Q38884170 | Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention |
| Q28086826 | HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth |
| Q90386579 | Human Cervical Epithelial Cells Release Antiviral Factors and Inhibit HIV Replication in Macrophages |
| Q39830543 | Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility |
| Q41961460 | Immunogenicity of the outer domain of a HIV-1 clade C gp120. |
| Q37533386 | Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. |
| Q33559031 | Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity |
| Q37208595 | Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. |
| Q38065425 | Molecular architecture and therapeutic potential of lectin mimics |
| Q35024164 | Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes |
| Q40168596 | NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles |
| Q61797852 | Overview of the Structure⁻Function Relationships of Mannose-Specific Lectins from Plants, Algae and Fungi |
| Q37767654 | Potential of carbohydrate-binding agents as therapeutics against enveloped viruses |
| Q35634404 | Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus |
| Q39756219 | Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. |
| Q38304461 | Primary structure and carbohydrate binding specificity of a potent anti-HIV lectin isolated from the filamentous cyanobacterium Oscillatoria agardhii |
| Q37052084 | Purification and characterization of a novel plant lectin from Pinellia ternata with antineoplastic activity |
| Q34446169 | Recent highlights in the development of new antiviral drugs |
| Q40204965 | Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. |
| Q33842989 | Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. |
| Q41888076 | Sialic acid on herpes simplex virus type 1 envelope glycoproteins is required for efficient infection of cells |
| Q91908886 | Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses |
| Q38305332 | Strict specificity for high-mannose type N-glycans and primary structure of a red alga Eucheuma serra lectin |
| Q34092638 | Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer |
| Q36248197 | Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins |
| Q34005185 | Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy |
| Q81410989 | Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV |
| Q38302147 | The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. |
| Q34005790 | The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins |
| Q27023390 | The hepatitis C virus glycan shield and evasion of the humoral immune response |
| Q35604541 | The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry |
| Q33498727 | The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential |
| Q39224771 | The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents |
Search more.